Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/biostatistics/kxv040 http://scihub22266oqcxt.onion/10.1093/biostatistics/kxv040 C5006115!5006115!26486139     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biostatistics 2016 ; 17 (2): 249-63 Nephropedia Template TP {{tp|p=26486139|t=2016. A robust Bayesian dose-finding design for phase I/II clinical trials |pdf=|usr=}}{{26486139}} gab.com Text A robust Bayesian dose-finding design for phase I/II clinical trials JO: Biostatistics http://www.kidney.de/pget.php?&tw=1&pmid=26486139 #FOAvip We propose a Bayesian phase I/II dose-finding trial design that simultaneously accounts for toxicity and efficacy. We model the toxicity and efficacy of investigational doses using a flexible Bayesian dynamic model, which borrows information across doses without imposing stringent parametric assumptions on the shape of the dose?toxicity and dose?efficacy curves. An intuitive utility function that reflects the desirability trade-offs between efficacy and toxicity is used to guide the dose assignment and selection. We also discuss the extension of this design to handle delayed toxicity and efficacy. We conduct extensive simulation studies to examine the operating characteristics of the proposed method under various practical scenarios. The results show that the proposed design possesses good operating characteristics and is robust to the shape of the dose?toxicity and dose?efficacy curves. Twit Text FOAVip A robust Bayesian dose-finding design for phase I/II clinical trials ????Biostatistics http://www.kidney.de/pget.php?&tw=1&pmid=26486139 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26486139 #FOAvip English Wikipedia <ref>{{Cite pmid|26486139}}</ref> A robust Bayesian dose-finding design for phase I/II clinical trials #MMPMID26486139 Liu S; Johnson VE Biostatistics 2016[Apr]; 17 (2): 249-63 PMID26486139show ga We propose a Bayesian phase I/II dose-finding trial design that simultaneously accounts for toxicity and efficacy. We model the toxicity and efficacy of investigational doses using a flexible Bayesian dynamic model, which borrows information across doses without imposing stringent parametric assumptions on the shape of the dose?toxicity and dose?efficacy curves. An intuitive utility function that reflects the desirability trade-offs between efficacy and toxicity is used to guide the dose assignment and selection. We also discuss the extension of this design to handle delayed toxicity and efficacy. We conduct extensive simulation studies to examine the operating characteristics of the proposed method under various practical scenarios. The results show that the proposed design possesses good operating characteristics and is robust to the shape of the dose?toxicity and dose?efficacy curves. äA robust Bayesian dose-finding design for phase I/II clinical trials (epmc).pdf DeepDyve Pubget Overpricing